



**Date: 16 October 2019**

**Sydney, Australia**

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

### **New Executive Appointments, Creation of U.S. Presence, and Board Changes**

---

- NOX has put in place the key executive structure aimed at bringing Veyonda<sup>®</sup> to market as a major new treatment for prostate cancer
  - Key U.S. appointment ahead of rising North American presence
  - An executive team with extensive drug development experience
  - Dr Beata Edling steps down as Non-Executive Director. Board to revert to 3 directors
- 

**Sydney, 16 October 2019:** Noxopharm (ASX: NOX) announces details of changes to its senior executive and Board structures.

#### Executive structure

Dr Graham Kelly remains **Executive Chairman**, and as the Company's Founder and senior executive, will continue to oversee the operations and strategic direction of the Company.

Ms Jeanette Bell remains as **Chief Operating Officer** and is responsible for the day-to-day management of the Noxopharm business.

Dr Gisela Mautner has been promoted from Global Medical Director to **Chief Medical Officer**. Dr Mautner is responsible for the Company's clinical trial activities and strategy.

Dr John Wilkinson remains as **Chief Scientific Officer** but will have a focus on supporting the Veyonda<sup>®</sup> clinical program. This is a required key focus with the program facing a significant increase in clinical activity in 2020 including the prospect of Veyonda<sup>®</sup> entering a registration study in 2020. Manufacturing and pre-clinical and regulatory support are expected to become areas of considerable activity.

Dr Olivier Laczka has been appointed as **Director of Drug Discovery and Research** and is charged with growing the Company's drug pipeline, with four programs currently underway.



### U.S. operations

Mr Greg Ambra has been appointed as **Senior Vice-President North American Operations**. Mr Ambra is a U.S. citizen charged with growing the Company's presence in the U.S. His role will be (i) to oversee the growth of the Company's North American clinical trial program, (ii) to grow the Company's presence and profile within the investment community and pharmaceutical industry, and (iii) to assist Dr Kelly in the Company's proposed dual listing in 2020.

### Board

Dr Beata Edling has resigned from the Board due to family reasons, effective immediately. The Board will revert to its original 3 directors and defer a replacement until it approaches the Company's proposed dual listing in 2020.

---

### **About Ms Jeanette Bell**

Jeanette has more than 30 years' experience in healthcare including 15 years at Eli Lilly in senior leadership roles in Europe, Asia Pacific and Japan. The scope of work in Asia Pacific involved co-developing the clinical strategy and operations plans for registration studies in China and Japan. In the role as COO, Jeanette will drive the delivery of the Noxopharm Clinical Development Plan as well as taking responsibility for all internal business activities.

### **About Dr Gisela Mautner**

Dr Mautner has a distinguished career in medical leadership roles within the pharmaceutical and biotech industries. She is a qualified medical doctor with a PhD in medicine, a Master's in Public Health (Harvard) and an MBA (Kellogg). For the last decade Dr Mautner has become deeply entrenched in new therapies in oncology that encompass small molecules, biologics, gene-modified viruses and radiopharmaceuticals for various cancer types, from early to late stage disease. Possessing a combination of medical and strategic skills, and the deep desire to help people with disease to live better lives, she has successfully launched new oncology drugs for two of the top ten global pharma companies. Balancing patient care and commercial interests are core to her success, as are her abilities in directing the medical strategies and operations and collaborating with internal and external parties to achieve results.

Dr Mautner is also an industry advocate and currently holds the role of VP of the Australian association for medical and scientific professionals in the pharmaceutical industry (APPA) which represents approximately 85% of all Medical Affairs professionals in Australia.

Having lived and worked in Europe, the USA, Asia and Australia, Dr Mautner is a citizen of the world. As Noxopharm negotiates its global journey, Dr Mautner's attunement to not only the commercial and regulatory but also to cultural implications of launching new drugs in international territories, will help to successfully deliver the Company's objectives.

Gisela is a medical doctor with over 20 years' experience in the pharma/biotech industry in Europe, USA and Australasia. In her early career Gisela was a research fellow at NIH, Bethesda, MD. Since then she has focused on bringing new drugs and therapies to market in senior roles in Medical Affairs at Merck/MSD, Bayer and Amgen.



#### **About Mr Greg Ambra**

Greg has over 20 years of experience in the clinical development industry, having held strategic leadership positions in industry-leading drug/device and CRO companies. Prior to Noxopharm, Greg was the founder and CEO of DZS Clinical Services, Inc., a CRO focused on supporting small to mid-size biotech organizations.

During his tenure at DZS, the company achieved consistent growth and expansion, resulting in multiple regulatory approvals globally and significant commercial success. Greg supported the successful sale of the company's proprietary software platform in 2017 and continued to lead the services organization through a successful acquisition by WDB Medical Group in 2018. Greg previously held various leadership positions at Baxter Healthcare, Convatec, and Campbell Alliance, a leading life sciences management consultant group.

Greg has a passion for bringing new therapeutics to patients by fostering a sense of urgency and a culture of excellence. He holds a master's degree in Medical Sciences from Boston University and is currently finalizing an MBA from William and Mary College.

#### **About Dr John Wilkinson**

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom. His research interests include drug development, virology, oncology and immunology, translating novel laboratory findings into human clinical trials that have previously resulted in numerous peer-reviewed publications.

#### **About Dr Olivier Laczka**

Olivier obtained a PhD in Biotechnology from the Autonomous University of Barcelona, Spain, in 2009, after completing a master's degree in applied biotechnology and microbiology and a bachelor's degree in biological sciences in France. For the first part of his career, Olivier conducted research as an academic in Spain and Australia. In 2015, he joined the biopharmaceutical industry as a senior research scientist, where he successfully managed and completed therapeutic drug development projects within GLP and cGMP environments, following the current regulatory requirements for early stages of drug development. Throughout his career, Olivier has developed an extensive experience in people and project management, as well as interacting with academic, government, and private entities or individuals, at the international level.

#### **About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

[www.noxopharm.com](http://www.noxopharm.com)

#### **Investor & Corporate Enquiries**

##### **Media Contact Australia**

Prue Kelly

M: 0459 022 445

E: [Prue.Kelly@noxopharm.com](mailto:Prue.Kelly@noxopharm.com)

##### **Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

##### **Media Contact USA:**

Frank de Maria

Purposeful Communications

T: +1 347 647 0284

E: [frank.demaria@purposefulcommunications.com](mailto:frank.demaria@purposefulcommunications.com)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.